ISRCTN77377400已完成不适用
Re-evaluation of the upper level of intake for zinc using novel molecular biomarkers of copper status
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •1. Healthy boys 7 to 8 years of age
- •2. Boys not taking a mineral supplement and have not taken a mineral supplement three months prior to commencing the study
- •3. Boys not taking sodium fluoride or aspirin
- •4. Boys living in Guelph, Ontario vicinity
- •5. Informed consent by the caregivers of the boys
- •6. Assent by the boys
排除标准
- •Individuals not fulfilling the above inclusion criteria.
研究者
相似试验
已完成
2 期
Phase II study of additional indication on extreme hypofractionated stereotactic body radiation therapy for prostate cancerProstate cancerJPRN-UMIN000032423Tokai university30
进行中（未招募）
不适用
Phase I/II study investigating increasing doses of bevacizumab in patients with malignant effusioMalignant effusion in cancer patients requiring frequent centesis, at least two within six weeksEUCTR2006-003230-15-ATniversity Clinic Internal Medicine I
进行中（未招募）
1 期
Etude de phase II d’intensification de dose dans les tumeurs germinales réfractaires et en rechute de mauvais pronostic Protocole TICE : Paclitaxel et Ifosfamide suivi par une intensification de Carboplatine et Etoposide avec adaptation individuelle de la dose du Carboplatine - Intensification tumeurs germinalestumeurs germinales réfractaires en rechuteMedDRA version: 9.1Level: PTClassification code 10061184Term: Germ cell cancerEUCTR2008-005068-14-FRInstitut Claudius Regaud93
进行中（未招募）
1 期
A Phase 1/2 Study with Ascending Dose in order to Evaluate the Safety and Effects on Progranulin Levels of investigational product under code LY3884963 in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM)Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN)MedDRA version: 21.1Level: PTClassification code: 10068968Term: Frontotemporal dementia Class: 100000004852CTIS2022-502942-29-01Prevail Therapeutics Inc.35
进行中（未招募）
1 期
A Phase 1/2 Study with Ascending Dose in order to Evaluate the Safety and Effects on Progranulin Levels of investigational product under code LY3884963 in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM)Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN)MedDRA version: 21.1Level: PTClassification code 10068968Term: Frontotemporal dementiaSystem Organ Class: 10029205 - Nervous system disordersEUCTR2019-003159-12-BEPrevail Therapeutics, a wholly-owned subsidiary of Eli Lilly and Company35